UNION therapeutics receives FDA Fast Track designation for oral orismilast for the treatment of moderate to severe hidradenitis suppurativa
FDA’s Fast Track designation for oral orismilast underscores the urgent need for new treatment options to fulfil the unmet medical need for people affected by moderate to severe hidradenitis suppurativa […]
UNION therapeutics announces positive topline results from the IASOS Phase 2b study of oral orismilast in patients with moderate to severe psoriasis
Primary endpoint at week 16 was met for all three active doses of oral orismilast in moderate to severe patients with psoriasis. Statistical significance reached already at the first […]
First large-scale analysis confirms that vulnerable patients remain at increased fatality to COVID-19 despite availability of vaccines
Analysis includes data from UK Kidney Association (UKKA) on 9,388 COVID-19 cases among kidney patients in the UK of which 924 were fatal (Dec 2020 to March 2022) The analyses […]
UNION therapeutics announces two peer-reviewed publications of preclinical and clinical Phase 2a data on orismilast
New insights into the pharmacological properties of orismilast and Phase 2a data published in peer-reviewed journal JEADV Data supports orismilast’s potential as a first-in-class or best-in-class treatment for a range […]
UNION therapeutics to present at the Dermatology Summit 2023
UNION invited to present orismilast at the Dermatology Summit 2023 Orismilast is a potent next-generation PDE4 inhibitor with broad anti-inflammatory properties in development as a first-in-class or best-in-class treatment for […]
UNION therapeutics and Innovent announce first subject dosed in a Chinese clinical Phase 1 study of orismilast, a novel PDE-4 inhibitor
Hellerup, Denmark and ROCKVILLE, M.D., Suzhou, China, 5 December 2022 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, and Innovent […]
UNION therapeutics completes 62 million DKK private placement to support clinical program
Hellerup, Denmark, 1 December 2022 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, today announced the completion of a […]
UNION therapeutics to present at the 6th Annual Dermatology Drug Development Summit
Data on pharmacological properties of orismilast to be presented on 2nd of November 2022 Orismilast is a potent next-generation PDE4 inhibitor with broad anti-inflammatory properties in development as a first-in-class […]
UNION therapeutics presents new data on orismilast at the 31st EADV Congress supporting orismilast’s potential as a first-in-class or best-in-class treatment for certain immunological diseases
Preclinical data presented in the oral presentation demonstrate that orismilast is a potent inhibitor of phosphodiesterase type-4 (PDE4), and that orismilast more selectively inhibit PDE4B and PDE4D subtypes which are […]
UNION therapeutics announces regulatory approval of Treatment Extension for the ongoing OSIRIS Phase 2a open label study with orismilast MR tablet for patients with Hidradenitis Suppurativa (HS)
OSIRIS is an investigator-initiated Phase 2a open label study, studying orismilast modified release (MR) tablet as a potential treatment for HS Treatment Extension gives the possibility to allow patients to […]